Matches in SemOpenAlex for { <https://semopenalex.org/work/W14747713> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W14747713 endingPage "4" @default.
- W14747713 startingPage "2671" @default.
- W14747713 abstract "To analyze the outcomes and adverse effects of bortezomib-based regimen for the treatment of multiple myeloma (MM) patients.A total of 110 MM patients were treated with a bortezomib-based regimen at our hospital from January 2006 to February 2010. The patients over 65 years old received bortezomib-prednisone ± thalidomide (PD±T) regimen or velcade-melphalan-prednisone (VMP) regimen therapy and the patients under 65 years old or resistant to PD±T regimen received bortezomib-doxorubicin-prednisone ± thalidomide (PAD±T) regimen therapy. The outcomes and adverse effects of bortezomib-based regimen were retrospectively evaluated.There were 47 newly-diagnosed MM patients and 63 relapsing/refractory MM patients. The overall remission (OR) rate was 76.4% (84/110) and the OR rate of newly-diagnosed MM patients was statistically higher than that of relapsing/refractory MM patients (83.0% vs 71.4%, P<0.05). The complete remission (CR)+very good partial remission (VGPR) rate in group bortezomib 1.0 mg/m2 was lower than that in group bortezomib 1.3 mg/m2 (newly-diagnosed 53.6% vs 73.7%, relapsing/refractory 28.9% vs 40.0%, both P<0.05). The OR rate of ISS III stage patients was as better as that of ISS I and II stage patients (newly-diagnosed 82.1% vs 83.6%, relapsing/refractory 69.2% vs 72.2%, both P>0.05). Thirteen newly-diagnosed MM patients underwent autologous stem cell transplantation (ASCT) after induced therapy and achieved a VGPR or above. The median follow-up time was 13.0 (6.0-20.0) months. Their conditions were stable except two patients with extramedullary plasmacytoma after ASCT. Thirteen relapsing/refractory MM patients were retreated with a bortezomib-based regimen. The CR rate was 15.4% (2/13), VGPR rate was 23.1% (3/13), partial remission (PR) rate was 23.1% (3/13), OR rate 61.5% (8/13) and the median duration of remission (DOR) was 6.7 (3.0-21.0) months. Six MM patients with extramedullary plasmacytoma were treated with a bortezomib-based regimen and all of them achieved a PR or above. The median DOR was 4.5 (2.0-10.0) months. The main adverse effects were peripheral neuropathy, thrombocytopenia, neutropenia, fatigue, gastrointestinal symptoms, anemia, etc.The bortezomib-based combination regimen is the front-line therapy for newly-diagnosed and relapsing/refractory MM patients." @default.
- W14747713 created "2016-06-24" @default.
- W14747713 creator A5018889104 @default.
- W14747713 creator A5083332923 @default.
- W14747713 date "2010-10-19" @default.
- W14747713 modified "2023-09-23" @default.
- W14747713 title "[Bortezomib-based regimen for the treatment of 110 multiple myeloma patients]." @default.
- W14747713 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21162894" @default.
- W14747713 hasPublicationYear "2010" @default.
- W14747713 type Work @default.
- W14747713 sameAs 14747713 @default.
- W14747713 citedByCount "2" @default.
- W14747713 countsByYear W147477132015 @default.
- W14747713 crossrefType "journal-article" @default.
- W14747713 hasAuthorship W14747713A5018889104 @default.
- W14747713 hasAuthorship W14747713A5083332923 @default.
- W14747713 hasConcept C121332964 @default.
- W14747713 hasConcept C126322002 @default.
- W14747713 hasConcept C141071460 @default.
- W14747713 hasConcept C142424586 @default.
- W14747713 hasConcept C197934379 @default.
- W14747713 hasConcept C2776364478 @default.
- W14747713 hasConcept C2777478702 @default.
- W14747713 hasConcept C2778684742 @default.
- W14747713 hasConcept C2778720950 @default.
- W14747713 hasConcept C2779050716 @default.
- W14747713 hasConcept C2779609412 @default.
- W14747713 hasConcept C2781413609 @default.
- W14747713 hasConcept C71924100 @default.
- W14747713 hasConcept C87355193 @default.
- W14747713 hasConcept C90924648 @default.
- W14747713 hasConceptScore W14747713C121332964 @default.
- W14747713 hasConceptScore W14747713C126322002 @default.
- W14747713 hasConceptScore W14747713C141071460 @default.
- W14747713 hasConceptScore W14747713C142424586 @default.
- W14747713 hasConceptScore W14747713C197934379 @default.
- W14747713 hasConceptScore W14747713C2776364478 @default.
- W14747713 hasConceptScore W14747713C2777478702 @default.
- W14747713 hasConceptScore W14747713C2778684742 @default.
- W14747713 hasConceptScore W14747713C2778720950 @default.
- W14747713 hasConceptScore W14747713C2779050716 @default.
- W14747713 hasConceptScore W14747713C2779609412 @default.
- W14747713 hasConceptScore W14747713C2781413609 @default.
- W14747713 hasConceptScore W14747713C71924100 @default.
- W14747713 hasConceptScore W14747713C87355193 @default.
- W14747713 hasConceptScore W14747713C90924648 @default.
- W14747713 hasIssue "38" @default.
- W14747713 hasLocation W147477131 @default.
- W14747713 hasOpenAccess W14747713 @default.
- W14747713 hasPrimaryLocation W147477131 @default.
- W14747713 hasRelatedWork W1968681191 @default.
- W14747713 hasRelatedWork W2340210278 @default.
- W14747713 hasRelatedWork W2349895913 @default.
- W14747713 hasRelatedWork W2350480662 @default.
- W14747713 hasRelatedWork W2353532459 @default.
- W14747713 hasRelatedWork W2363734051 @default.
- W14747713 hasRelatedWork W2379437729 @default.
- W14747713 hasRelatedWork W2389251362 @default.
- W14747713 hasRelatedWork W2390144486 @default.
- W14747713 hasRelatedWork W2415584125 @default.
- W14747713 hasRelatedWork W2546977765 @default.
- W14747713 hasRelatedWork W2563955350 @default.
- W14747713 hasRelatedWork W2570467653 @default.
- W14747713 hasRelatedWork W2573079206 @default.
- W14747713 hasRelatedWork W2581822990 @default.
- W14747713 hasRelatedWork W2588317984 @default.
- W14747713 hasRelatedWork W2588946684 @default.
- W14747713 hasRelatedWork W2591725776 @default.
- W14747713 hasRelatedWork W3196090424 @default.
- W14747713 hasRelatedWork W3657330 @default.
- W14747713 hasVolume "90" @default.
- W14747713 isParatext "false" @default.
- W14747713 isRetracted "false" @default.
- W14747713 magId "14747713" @default.
- W14747713 workType "article" @default.